These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

130 related articles for article (PubMed ID: 38270288)

  • 1. Correction to: TAS2940, A novel brain-penetrable pan-ERBB inhibitor, for tumors with HER2 and EGFR aberrations.
    Cancer Sci; 2024 May; 115(5):1718. PubMed ID: 38270288
    [No Abstract]   [Full Text] [Related]  

  • 2. TAS2940, a novel brain-penetrable pan-ERBB inhibitor, for tumors with HER2 and EGFR aberrations.
    Oguchi K; Araki H; Tsuji S; Nakamura M; Miura A; Funabashi K; Osada A; Tanaka S; Suzuki T; Kobayashi SS; Mizuarai S
    Cancer Sci; 2023 Feb; 114(2):654-664. PubMed ID: 36282234
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Dacomitinib, but not lapatinib, suppressed progression in castration-resistant prostate cancer models by preventing HER2 increase.
    Jathal MK; Steele TM; Siddiqui S; Mooso BA; D'Abronzo LS; Drake CM; Whang YE; Ghosh PM
    Br J Cancer; 2019 Jul; 121(3):237-248. PubMed ID: 31209328
    [TBL] [Abstract][Full Text] [Related]  

  • 4. An ERBB1-3 Neutralizing Antibody Mixture With High Activity Against Drug-Resistant HER2+ Breast Cancers With ERBB Ligand Overexpression.
    Schwarz LJ; Hutchinson KE; Rexer BN; Estrada MV; Gonzalez Ericsson PI; Sanders ME; Dugger TC; Formisano L; Guerrero-Zotano A; Red-Brewer M; Young CD; Lantto J; Pedersen MW; Kragh M; Horak ID; Arteaga CL
    J Natl Cancer Inst; 2017 Nov; 109(11):. PubMed ID: 29059433
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comprehensive analysis of the ErbB receptor family in pediatric nervous system tumors and rhabdomyosarcoma.
    Varlet P; Bouffet E; Casanova M; Giangaspero F; Antonelli M; Hargrave D; Ladenstein R; Pearson A; Hawkins C; König FB; Rüschoff J; Schmauch C; Bühnemann C; Garin-Chesa P; Schweifer N; Uttenreuther-Fischer M; Gibson N; Ittrich C; Krämer N; Solca F; Stolze B; Geoerger B
    Pediatr Blood Cancer; 2022 Jan; 69(1):e29316. PubMed ID: 34546642
    [TBL] [Abstract][Full Text] [Related]  

  • 6. An heregulin-EGFR-HER3 autocrine signaling axis can mediate acquired lapatinib resistance in HER2+ breast cancer models.
    Xia W; Petricoin EF; Zhao S; Liu L; Osada T; Cheng Q; Wulfkuhle JD; Gwin WR; Yang X; Gallagher RI; Bacus S; Lyerly HK; Spector NL
    Breast Cancer Res; 2013; 15(5):R85. PubMed ID: 24044505
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Human breast cancer cells harboring a gatekeeper T798M mutation in HER2 overexpress EGFR ligands and are sensitive to dual inhibition of EGFR and HER2.
    Rexer BN; Ghosh R; Narasanna A; Estrada MV; Chakrabarty A; Song Y; Engelman JA; Arteaga CL
    Clin Cancer Res; 2013 Oct; 19(19):5390-401. PubMed ID: 23948973
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Targeting HER2 aberrations as actionable drivers in lung cancers: phase II trial of the pan-HER tyrosine kinase inhibitor dacomitinib in patients with HER2-mutant or amplified tumors.
    Kris MG; Camidge DR; Giaccone G; Hida T; Li BT; O'Connell J; Taylor I; Zhang H; Arcila ME; Goldberg Z; Jänne PA
    Ann Oncol; 2015 Jul; 26(7):1421-7. PubMed ID: 25899785
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Phase 2 trial of afatinib, an ErbB family blocker, in solid tumors genetically screened for target activation.
    Kwak EL; Shapiro GI; Cohen SM; Becerra CR; Lenz HJ; Cheng WF; Su WC; Robohn M; Le Maulf F; Lobmeyer MT; Chand VK; Iafrate AJ
    Cancer; 2013 Aug; 119(16):3043-51. PubMed ID: 23775486
    [TBL] [Abstract][Full Text] [Related]  

  • 10. ZD1839, a specific epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor, induces the formation of inactive EGFR/HER2 and EGFR/HER3 heterodimers and prevents heregulin signaling in HER2-overexpressing breast cancer cells.
    Anido J; Matar P; Albanell J; Guzmán M; Rojo F; Arribas J; Averbuch S; Baselga J
    Clin Cancer Res; 2003 Apr; 9(4):1274-83. PubMed ID: 12684395
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Frequency, impact and a preclinical study of novel
    Elster N; Toomey S; Fan Y; Cremona M; Morgan C; Weiner Gorzel K; Bhreathnach U; Milewska M; Murphy M; Madden S; Naidoo J; Fay J; Kay E; Carr A; Kennedy S; Furney S; Mezynski J; Breathhnach O; Morris P; Grogan L; Hill A; Kennedy S; Crown J; Gallagher W; Hennessy B; Eustace A
    Ther Adv Med Oncol; 2018; 10():1758835918778297. PubMed ID: 30023006
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A phase I trial of the pan-ERBB inhibitor neratinib combined with the MEK inhibitor trametinib in patients with advanced cancer with EGFR mutation/amplification, HER2 mutation/amplification, HER3/4 mutation or KRAS mutation.
    Piha-Paul SA; Tseng C; Tran HT; Gao M; Karp DD; Subbiah V; Tsimberidou AM; Kawedia JD; Fu S; Pant S; Yap TA; Morris VK; Kee BK; Blum Murphy M; Lim J; Meric-Bernstam F
    Cancer Chemother Pharmacol; 2023 Aug; 92(2):107-118. PubMed ID: 37314501
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The pan-erbB tyrosine kinase inhibitor CI-1033 inhibits human esophageal cancer cells in vitro and in vivo.
    Ako E; Yamashita Y; Ohira M; Yamazaki M; Hori T; Kubo N; Sawada T; Hirakawa K
    Oncol Rep; 2007 Apr; 17(4):887-93. PubMed ID: 17342332
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Human epidermal growth factor receptor 2-positive metastatic breast cancer with novel epidermal growth factor receptor -ZNF880 fusion and epidermal growth factor receptor E114K mutations effectively treated with pyrotinib: A case report.
    Yue L; Wentao L; Xin Z; Jingjing H; Xiaoyan Z; Na F; Tonghui M; Dalin L
    Medicine (Baltimore); 2020 Dec; 99(51):e23406. PubMed ID: 33371069
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Expression of HER2/c-erbB-2, EGFR Protein in Gastric Carcinoma and its Clinical Significance.
    Cheng G; Mei Y; Pan X; Liu M; Wu S
    Open Life Sci; 2019 Jan; 14():119-125. PubMed ID: 33817143
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A new model system identifies epidermal growth factor receptor-human epidermal growth factor receptor 2 (HER2) and HER2-human epidermal growth factor receptor 3 heterodimers as potent inducers of oesophageal epithelial cell invasion.
    Fichter CD; Przypadlo CM; Buck A; Herbener N; Riedel B; Schäfer L; Nakagawa H; Walch A; Reinheckel T; Werner M; Lassmann S
    J Pathol; 2017 Dec; 243(4):481-495. PubMed ID: 28940194
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Clinicopathologic Characteristics, Treatment Outcomes, and Acquired Resistance Patterns of Atypical EGFR Mutations and HER2 Alterations in Stage IV Non-Small-Cell Lung Cancer.
    Patil T; Mushtaq R; Marsh S; Azelby C; Pujara M; Davies KD; Aisner DL; Purcell WT; Schenk EL; Pacheco JM; Bunn PA; Camidge DR; Doebele RC
    Clin Lung Cancer; 2020 May; 21(3):e191-e204. PubMed ID: 31859066
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Breast cancer expressing the activated HER2/neu is sensitive to gefitinib in vitro and in vivo and acquires resistance through a novel point mutation in the HER2/neu.
    Piechocki MP; Yoo GH; Dibbley SK; Lonardo F
    Cancer Res; 2007 Jul; 67(14):6825-43. PubMed ID: 17638894
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A novel proteotoxic combination therapy for EGFR+ and HER2+ cancers.
    Wang M; Ferreira RB; Law ME; Davis BJ; Yaaghubi E; Ghilardi AF; Sharma A; Avery BA; Rodriguez E; Chiang CW; Narayan S; Heldermon CD; Castellano RK; Law BK
    Oncogene; 2019 May; 38(22):4264-4282. PubMed ID: 30718919
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Frequent overexpression of ErbB--receptor family members in brain metastases of non-small cell lung cancer patients.
    Berghoff AS; Magerle M; Ilhan-Mutlu A; Dinhof C; Widhalm G; Dieckman K; Marosi C; Wöhrer A; Hackl M; Zöchbauer-Müller S; Preusser M; Birner P
    APMIS; 2013 Dec; 121(12):1144-52. PubMed ID: 23756255
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.